全文获取类型
收费全文 | 3679篇 |
免费 | 223篇 |
国内免费 | 32篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 313篇 |
妇产科学 | 40篇 |
基础医学 | 449篇 |
口腔科学 | 79篇 |
临床医学 | 343篇 |
内科学 | 882篇 |
皮肤病学 | 58篇 |
神经病学 | 278篇 |
特种医学 | 405篇 |
外国民族医学 | 2篇 |
外科学 | 394篇 |
综合类 | 39篇 |
一般理论 | 1篇 |
预防医学 | 222篇 |
眼科学 | 37篇 |
药学 | 211篇 |
1篇 | |
中国医学 | 7篇 |
肿瘤学 | 169篇 |
出版年
2021年 | 40篇 |
2020年 | 33篇 |
2019年 | 37篇 |
2018年 | 69篇 |
2017年 | 52篇 |
2016年 | 35篇 |
2015年 | 59篇 |
2014年 | 58篇 |
2013年 | 92篇 |
2012年 | 76篇 |
2011年 | 82篇 |
2010年 | 89篇 |
2009年 | 140篇 |
2008年 | 130篇 |
2007年 | 145篇 |
2006年 | 132篇 |
2005年 | 119篇 |
2004年 | 106篇 |
2003年 | 107篇 |
2002年 | 101篇 |
2001年 | 112篇 |
2000年 | 120篇 |
1999年 | 110篇 |
1998年 | 129篇 |
1997年 | 141篇 |
1996年 | 128篇 |
1995年 | 99篇 |
1994年 | 94篇 |
1993年 | 102篇 |
1992年 | 55篇 |
1991年 | 56篇 |
1990年 | 61篇 |
1989年 | 80篇 |
1988年 | 90篇 |
1987年 | 68篇 |
1986年 | 74篇 |
1985年 | 60篇 |
1984年 | 48篇 |
1983年 | 36篇 |
1982年 | 32篇 |
1981年 | 40篇 |
1980年 | 33篇 |
1979年 | 31篇 |
1978年 | 35篇 |
1977年 | 52篇 |
1976年 | 40篇 |
1975年 | 35篇 |
1970年 | 33篇 |
1969年 | 34篇 |
1968年 | 33篇 |
排序方式: 共有3934条查询结果,搜索用时 265 毫秒
1.
Birth weight on 12,644 singleton infants from 6,196 sibships born in Maryland between 1980 and 1984 were used to estimate the effects of nine maternal and infant covariates on the sibship correlation in birth weight. Assuming a homogeneous correlation across all families, the estimated intraclass correlation was 0.4664 (+/- 0.0099). This high sibship correlation makes it possible to predict, with reasonable accuracy, the birth weight of a child given information on previous sibs, as well as covariates on the mother and/or infant pertinent to a given pregnancy. The reduction in variance associated with incorporating information on the nine covariates used here was approximately equal to that obtained by conditioning on a single previous sib. Testing for heterogeneity in correlation among different groups of families showed that a crude measure of parity (first live birth vs. other), time between births, mother's marital status, and maternal age at the birth of the last child significantly influenced the sibship correlation in birth weight. 相似文献
2.
3.
M Lum R Fontaine R Elie A Ontiveros 《Progress in neuro-psychopharmacology & biological psychiatry》1991,15(2):269-273
1. After drug discontinuation and 1 week placebo washout, 12 patients with panic disorders received, for 6 weeks, either placebo or sodium divalproex. During 6 consecutive weeks, alternate medication was given. 2. Severity of panic and anxiety attacks was improved only in patients receiving sodium divalproex as a first medication. 3. Protracted benzodiazepine effects may occur in the dichotomous antipanic activity of sodium divalproex. 相似文献
4.
ME BURGE AM JOSHUA CM McNEIL R HUI MJ BOYER R ABRAHAM 《Asia-Pacific Journal of Clinical Oncology》2005,1(1):47-52
Background: Pemetrexed and cisplatin have recently been shown to significantly improve survival compared with cisplatin alone. However, there are only limited data reflecting teaching hospital experience outside a clinical trial. Pemetrexed has only been available in Australia on a restricted basis since 2002. We reviewed our experience of patients treated on the Australian ‘Special Access Scheme’ at three major thoracic oncology units. Methods: Charts were reviewed for all patients enrolled on the scheme. Data was extracted on age, World Health Organization (WHO) performance status, histology, prior therapy, time from diagnosis to starting pemetrexed, chemotherapy (pemetrexed alone or with a platinum), cycle number, response rate, actuarial progression‐free and overall survival. Doses were cisplatin 75 mg/m2 or carboplatin AUC = 5 and pemetrexed 500 mg/m2 every 21 days. Results: 52 patients (32 male and 20 female) were reviewed. Median age was 58 years and 88% were WHO 0–1. Histology included 54% epithelial, 17% biphasic (epithelial and sarcomatoid) and 21% undefined. The median time from diagnosis to administration of pemetrexed was 145 days. Sixty‐five percent had minimal surgical intervention with video assisted thoracoscopy, pleurodesis and biopsy, while 19% had received prior palliative radiation. Seventy‐one percent were chemotherapy naïve, the remaining 29% having received previous platinum and/or gemcitabine regimens. Twenty‐three percent had pemetrexed alone, 35% in combination with carboplatin and 42% with cisplatin. The median number of cycles was 4 (range 1–13). The response rate was 33%. No toxicity was observed in 20% grade 3–4 toxicity in 10% (majority nausea/vomiting). The median progression‐free and overall survival times from starting pemetrexed were 184 days and 298 days, respectively. Conclusions: Pemetrexed‐based regimens are safe and effective in a community setting in malignant mesothelioma. 相似文献
5.
Isabelle Durieu Evelyne Vericel Daniel Guichardant Hubert Roth Jean-Paul Steghens Jocelyne Drai Raphaele Nove Josserand Eric Fontaine Michel Lagarde Gabriel Bellon 《Journal of cystic fibrosis》2007,6(5):320-326
BACKGROUND: An imbalance in the ratio of arachidonic acid and docosahexaenoic acid (DHA) was found in cystic fibrosis (CF) affected tissues and was suggested to promote inflammation. Several studies have shown that the long chain n-3 fatty acids reduced inflammatory activity while others have highlighted prooxidant activity of DHA at high concentrations. The aim of our study was to evaluate the effects of an intravenous fish-oil emulsion enriched with n-3 FA in patients with CF on plasma and platelet FA composition and peroxidation markers. METHODS: 13 patients with CF received one IV emulsion per week of 2 mL/kg fish-oil n-3 emulsion for 12 weeks. RESULTS: There was a significant increase in 20:5 n-3 and 22:6 n-3 platelet FA composition, no variation in 20:4 n-6, a decrease in n-9. There was no variation in plasma FA composition. Specific urinary markers of lipid peroxidation derived from n-3 and n-6 showed a very high level before infusion compared with usual values in healthy subjects which was not affected by treatment. A significant weight loss and a decrease in reduced glutathione were observed in adult patients. CONCLUSIONS: The intravenous administration of n-3 FA in CF patients induced a significant modification in platelet FA composition but no modification of oxidative markers. However, the weight loss and the decreased level in reduced glutathione observed in adult patients may suggest a potential deleterious activity for some patients. Further studies are necessary to determine the optimal dose and route for long chain FA administration required to reach a potential beneficial effect. 相似文献
6.
7.
CM Reid M. Nelson P. Beckinsale P. Ryan LMH Wing LJ Beilin MA Brown GLR Jennings CI Johnston J. Marley JJ McNeil TO Morgan J. Shaw ID Steven MJ West 《Clinical and experimental pharmacology & physiology》1997,24(5):370-373
1. The present study aimed to determine the feasibility of conducting a 5 year cardiovascular outcome trial of the treatment of 6000 elderly hypertensive patients in Australian general practices. 2. General practitioners (GPs) were invited to participate by mail and personal follow-up. Patient records were reviewed to identify subjects for a blood pressure (BP) screening programme. Blood pressure was measured on three occasions and eligible subjects were included if the average BP was 160 mmHg systolic or 90 mmHg diastolic if systolic BP was 140 mmHg. 3. Seven hundred and forty-one GPs were approached and 89 were enrolled in the study (12% of mail invites and 75% of those receiving a personal contact). In 16 practices where screening was completed, 82 000 records were reviewed to identify 4% patients eligible for screening. Twenty-two per cent of eligible subjects attended screening. Of 1938 subjects screened, 180 (9%) had BP 5=160/90 mmHg. Forty-seven percent of subjects (n = 916) were receiving antihypertensive therapy and 184 (20%) were withdrawn from therapy. One hundred and sixteen (63%) of these subjects had BP return to study entry levels within 6 weeks. Fifty-seven newly diagnosed and 81 previously treated subjects were randomized (7% of the screened population). 4. Based on the high participation rate of GPs, the response rate of patients to attend a BP screening programme and the 7% randomization to screening ratio for entry into the study, the ANBP2 pilot study has demonstrated that it is feasible to recruit subjects from Australian general practices to a cardiovascular outcome trial. 相似文献
8.
9.
10.